Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS906 phase 2 study in C3 glomerulopathy and idiopathic immune complex-mediated glomerulonephritis
2023-508669-33-00Phase 2Completed
- Sponsor
- Omeros Corporation
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of zaltenibart in Complement 3 glomerulopathy (C3G) and idiopathic immune complex glomerulonephritis (ICGN), sponsored by Omeros Corporation. Primary endpoint: Safety and tolerability. Started Jan 2024; status: completed.
02
Drugs
zaltenibart
03
Conditions
Complement 3 glomerulopathy (C3G)idiopathic immune complex glomerulonephritis (ICGN)
Beyond the preview
Go deeper on 2023-508669-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508669-33-00.